Overcoming Drug Resistance in Multiple Myeloma
$83,332U54FY2021CANIH
Mayo Clinic Arizona, Scottsdale AZ
Investigators
Linked publications, trials & patents
Paper 39364307Paper 38714690Paper 38233233Paper 37934799Paper 37767768Paper 37217482Paper 36877894Paper 36051067Paper 35743843Paper 35264575Paper 35195258Paper 34258584Paper 34236997Paper 32954360Paper 32724061Paper 32561655Paper 32393731Paper 31582538Paper 31439946Paper 30850386Paper 30741931Paper 30683909Paper 30607001Paper 30510245Paper 30300141Paper 30198908Paper 30093382Paper 29774113Paper 29669929Paper 29558366Paper 29242603Paper 28665416Paper 28633670Paper 28362441
Abstract
This supplement will allow the Mayo Clinic/University of Minnesota Myeloma DRSC to provide unique resources and support to Dr. Constantine Mitsiades? supplement to his U01. Dr. Mitsiades is studying the role of glycosylation in drug resistance and in collaboration with the DRSC will analyze myeloma cell lines and drug refractor patient samples for alterations in glycosylation. In addition, the DRSC will provide a unique animal model of myeloma that will be used for in vivo selection of CRISPR targets that mediate drug resistance to immunomodulatory drugs, proteasome inhibitors and T-cell engagers.
View original record on NIH RePORTER →